138 related articles for article (PubMed ID: 26020391)
1. Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma.
Mackiewicz J; Karczewska-Dzionk A; Laciak M; Kapcinska M; Wiznerowicz M; Burzykowski T; Zakowska M; Rose-John S; Mackiewicz A
Medicine (Baltimore); 2015 May; 94(21):e853. PubMed ID: 26020391
[TBL] [Abstract][Full Text] [Related]
2. Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results.
Mackiewicz J; Burzykowski T; Iżycki D; Mackiewicz A
J Immunother Cancer; 2018 Nov; 6(1):134. PubMed ID: 30486884
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection.
Mackiewicz A; Mackiewicz J; Wysocki PJ; Wiznerowicz M; Kapcinska M; Laciak M; Rose-John S; Izycki D; Burzykowski T; Karczewska-Dzionk A
Expert Opin Investig Drugs; 2012 Jun; 21(6):773-83. PubMed ID: 22577889
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6.
Czerwinska P; Rucinski M; Wlodarczyk N; Jaworska A; Grzadzielewska I; Gryska K; Galus L; Mackiewicz J; Mackiewicz A
Oncoimmunology; 2020; 9(1):1710063. PubMed ID: 32002306
[TBL] [Abstract][Full Text] [Related]
5. Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients.
Kwiatkowska-Borowczyk E; Czerwińska P; Mackiewicz J; Gryska K; Kazimierczak U; Tomela K; Przybyła A; Kozłowska AK; Galus Ł; Kwinta Ł; Dondajewska E; Gąbka-Buszek A; Żakowska M; Mackiewicz A
Oncoimmunology; 2018; 7(11):e1509821. PubMed ID: 30377573
[TBL] [Abstract][Full Text] [Related]
6. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
7. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
[TBL] [Abstract][Full Text] [Related]
8. BNIP3L Is a New Autophagy Related Prognostic Biomarker for Melanoma Patients Treated With AGI-101H.
Kazimierczak U; Kolenda T; Kowalczyk D; Mackiewicz J; Mackiewicz A
Anticancer Res; 2020 Jul; 40(7):3723-3732. PubMed ID: 32620611
[TBL] [Abstract][Full Text] [Related]
9. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
[TBL] [Abstract][Full Text] [Related]
10. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
O'Day SJ; Boasberg PD; Piro L; Kristedja TS; Wang HJ; Martin M; Deck R; Ames P; Shinn K; Kim H; Fournier P; Gammon G
Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516
[TBL] [Abstract][Full Text] [Related]
11. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma.
Lee P; Wang F; Kuniyoshi J; Rubio V; Stuges T; Groshen S; Gee C; Lau R; Jeffery G; Margolin K; Marty V; Weber J
J Clin Oncol; 2001 Sep; 19(18):3836-47. PubMed ID: 11559721
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
14. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
[TBL] [Abstract][Full Text] [Related]
15. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
Rixe O; Borel C; Paraiso D; Benhammouda A; Petit T; Antoine E; Bizzari JP; Auclerc G; Soubrane C; Weil M
Melanoma Res; 1995 Dec; 5(6):419-24. PubMed ID: 8589616
[TBL] [Abstract][Full Text] [Related]
16. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
17. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Robert C; Ribas A; Schachter J; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil CM; Lotem M; Larkin JMG; Lorigan P; Neyns B; Blank CU; Petrella TM; Hamid O; Su SC; Krepler C; Ibrahim N; Long GV
Lancet Oncol; 2019 Sep; 20(9):1239-1251. PubMed ID: 31345627
[TBL] [Abstract][Full Text] [Related]
19. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
Lian B; Si L; Cui C; Chi Z; Sheng X; Mao L; Li S; Kong Y; Tang B; Guo J
Clin Cancer Res; 2013 Aug; 19(16):4488-98. PubMed ID: 23833309
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
